
What will the FDA's decision be on Vamikibart by Genentech on or before July 31, 2027?
If the FDA's decision on Vamikibart by Genentech on or before July 31, 2027 is a full approval or an accelerated approval, the market resolves to Yes. Secondary rules: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Early close condition: This market will close early if the FDA issues a decision on Vamikibart before Aug 1, 2027
